StageSeries A - II | Alive
Last Raised$84M | 9 mos ago
Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+20 points in the past 30 days
About Aktis Oncology
Aktis Oncology is a biotechnology company that discovers and develops a class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Its approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. The firm serves clients operating in the healthcare sector. It was founded in 2020 and is based in Cambridge, Massachusetts.
Missing: Aktis Oncology's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aktis Oncology's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aktis Oncology
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aktis Oncology is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Latest Aktis Oncology News
May 12, 2023
News provided by Share this article Share this article CAMBRIDGE, Mass., May 12, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced Matthew Roden, PhD, President and Chief Executive Officer, and Shulamit Ron-Bigger, PhD, Chief Operating Officer, will participate in the 2023 Guggenheim Healthcare Talks: Radiopharmaceuticals Day, held on May 15 in New York City. Alongside the leading thinkers in cancer research, Aktis senior leadership will provide a company overview in a fireside chat at 2:10 pm ET, as well as participate in one-on-one investor meetings. About Aktis Oncology Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. To learn more about Aktis Oncology, visit www.aktisoncology.com . SOURCE Aktis Oncology
Aktis Oncology Frequently Asked Questions (FAQ)
When was Aktis Oncology founded?
Aktis Oncology was founded in 2020.
Where is Aktis Oncology's headquarters?
Aktis Oncology's headquarters is located at Cambridge.
What is Aktis Oncology's latest funding round?
Aktis Oncology's latest funding round is Series A - II.
How much did Aktis Oncology raise?
Aktis Oncology raised a total of $156M.
Who are the investors of Aktis Oncology?
Investors of Aktis Oncology include MPM Capital, EcoR1 Capital, Vida Ventures, Bristol-Myers Squibb, Novartis and 12 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.